Abstract:Objective:To investigate the relationship between recurrence and the level of Foxp3 + regulatory T cells (Tregs) in peripheral blood in patients with relapsed refractory acute lymphoblastic leukemia (R/R ALL) after treatment with chimeric antigen receptor T-Cell immunotherapy (CAR-T). Method:From January 2016 to January 2019, 43 patients with R/R ALL relapsed and refractory acute lymphoblastic leukemia in Affiliated Hospital of Xuzhou Medical University were selected as the study group, and 43 healthy people in the same period were selected as the control group. Fasting peripheral blood samples were taken after admission to the hospital to determine the ratio of T cell, CD4 + CD25 + Tregs, CD4 + CD25 + Foxp3 + Tregs using flow cytometry. and CAR-T cell immunotherapy was used.The proportion of T cell, CD4 + CD25 + Tregs, CD4 + CD25 + Foxp3 + Tregs in the study group and the control group, patients with different curative effects and different prognostic effects were counted, and the correlation between each index and curative effect and prognosis was analyzed. Result:The proportion of T cells, CD4 + CD25 + Tregs and CD4 + CD25 + Foxp3 + Tregs in the study group were (67.32±13.29)%, (5.40±1.35)%, (4.81±1.28)%, which were significantly higher than those in the control group [(25.81±7.61)%, (3.10±0.66)%, (2.80±0.75)% ](all P values <0.05). The percentage of T cells, CD4 + CD25 + Tregs and CD4 + CD25 + Foxp3 + Tregs in patients with partial remission were (46.18±10.22)%, (4.13±1.12)%, (3.64±0.91)%, respectively, while those without remission were (68.29±14.13)%, (5.51±1.40)%, (4.93±1.32)%, respectively .The proportion of T cell, CD4 + CD25 + Tregs and CD4 + CD25 + Foxp3 + Tregs in complete remission group were (30.79±6.53)%, (3.29±0.73)%, and (2.91±0.80)%, respectively, which were lower than those of partial remission (all P values <0.05) .The cell, CD4 + CD25 + Tregs and CD4 + CD25 + Foxp3 + Tregs were (29.79±7.01)%, (3.18±0.75) and (2.86±0.79)%, respectively. The recurrence rates were (66.13±14.06)%, (5.33±1.30)%, (4.77±1.13)%, respectively. The levels of T cells, CD4 + CD25 + Tregs and CD4 + CD25 + Foxp3 + Tregs were (29.79±7.01)%, (3.18±0.75)% and (2.86±0.79)%, respectively.T Cells, CD4 + CD25 + Tregs, CD4 + CD25 + Foxp3 + Tregs were negatively correlated with clinical efficacy and prognosis ( r=-0.661, -0.791, -0.766, -0.621, -0.761, -0.772, all P values <0.05). Conclusion:Foxp3 + Tregs levels in peripheral blood of patients with relapsed and refractory acute lymphoblastic leukemia R/R ALL were abnormal. There were significant differences in CD4 + CD25 + Foxp3 + Tregs levels in patients with different curative effects and relapse conditions after CAR-T cell immunotherapy, and there was a significant negative correlation between them.

The difference of CD4+CD25+ regulatory T cells and Foxp3 expression in non-small cell lung cancer patients with different lymph node metastasis status

The variation of CD4 + CD25 + regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN

Expression of regulatory T cells in the peripheral blood and its clinical significance in patients with non-small cell lung cancer

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

Study on the value of Foxp3 + Tregs level in peripheral blood of patients with relapsed and refractory acute lymphoblastic leukemia after CAR-T cell therapy

The effect of CD4~+C25~+Foxp3~+ iTreg on the pathogenesis of laryngeal squamous cell carcinoma

Expression of PD-L1 and TGF-βin Non-small Cell Lung Cancer and Its Clinical Significance

Tumor-infiltrating CD8+ and FOXP3+ Lymphocytes Before and after Neoadjuvant Chemotherapy in Cervical Cancer

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

[Influence of FOLFOX Regimen on the Immunologic Function in Patients with Advanced Colorectal Cancer].

Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients

CD13+CD4+CD25hiregulatory T Cells Exhibit Higher Suppressive Function and Increase with Tumor Stage in Non-Small Cell Lung Cancer Patients

Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer

In situ analysis of FOXP3+ regulatory T cells and myeloid dendritic cells in human colorectal cancer tissue and tumor-draining lymph node.

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

Immune Function Changes of Non-Small Cell Lung Cancer Patients after Chemotherapy

Expression and Clinical Significance of Regulatory T Cells in Patients with Colon Cancer

Study on Peripheral Blood T Lymphocyte Subsets of Patients with Lung Cancer and Lung Infection

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma

Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer